Table 3.
CST characterization in the study population by HIV and HPV status in women persistently negative for HPV (HPV–), persistently positive for hrHPV (hrHPV + +) and persistently positive for non hrHPV (non hrHPV + +).
| Vaginal community at baseline | ||||||||
|---|---|---|---|---|---|---|---|---|
| HIV negative women | HIV positive women | |||||||
| N = 69 (%) | HPV−− n = 46 (%) |
hrHPV++ n = 14 (%) |
Non hrHPV++ n = 9 (%) |
N = 142 (%) | HPV−− n = 71 (%) |
hrHPV++ n = 57 (%) |
Non hrHPV++ n = 14 (%) |
|
| CST I | 6 (9) | 2 (4) | 1 (7) | 3 (33) | 11 (8) | 4 (6) | 6 (11) | 1 (7) |
| CST II | 7 (10) | 5 (11) | 0 (0) | 2 (22) | 3 (2) | 1 (1) | 2 (4) | 0 (0) |
| CST III | 10 (15) | 7 (15) | 2 (14) | 1 (11) | 13 (9) | 7 (10) | 5 (9) | 1 (7) |
| CST I-B | 4 (6) | 4 (9) | 0 (0) | 0 (0) | 37 (26) | 19 (27) | 16 (28) | 2 (14) |
| CST IV-B | 26 (38) | 17 (37) | 9 (64) | 0 (0) | 38 (27) | 17 (24) | 17 (30) | 4 (29) |
| Missing CST | 16 (23) | 11 (24) | 2 (14) | 3 (33) | 40 (28) | 23 (32) | 11 (19) | 6 (43) |
| Vaginal community at follow-up | ||||||||
|---|---|---|---|---|---|---|---|---|
| HIV negative women | HIV positive women | |||||||
| N = 69 (%) | HPV−− n = 46 (%) |
hrHPV++ n = 14 (%) |
Non hrHPV++ n = 9 (%) |
N = 142 (%) |
HPV−− n = 71 (%) |
hrHPV++ n = 57 (%) |
Non hrHPV++ n = 14 (%) |
|
| CST I | 11 (16) | 7 (15) | 1 (7) | 3 (33) | 20 (14) | 10 (14) | 9 (16) | 1 (7) |
| CST II | 2 (3) | 1 (2) | 1 (7) | 0 (0) | 21 (15) | 7 (10) | 8 (14) | 6 (43) |
| CST III | 21 (30) | 15 (33) | 5 (36) | 1 (11) | 8 (6) | 4 (6) | 4 (7) | 0 (0) |
| CST I-B | 2 (3) | 2 (4) | 0 (0) | 0 (0) | 42 (32) | 25 (35) | 16 (28) | 1 (7) |
| CST IV-B | 21 (30) | 13 (28) | 5 (36) | 3 (33) | 50 (35) | 25 (35) | 20 (35) | 5 (36) |
| Missing CST | 12 (17) | 8 (17) | 2 (14) | 2 (22) | 1 (0) | 0 (0) | 0 (0) | 1 (7) |
N All participants included in analysis.
HPV−− Negative for HPV at both baseline and follow up visits.
hrHPV++ Positive for hrHPV at both baseline and follow up visits.
Non hrHPV++ Persistently positive for non hrHPV at baseline and follow up visits. This group includes women positive for low risk HPV at baseline and positive for low risk HPV at follow up; positive for low risk HPV at baseline and positive for hrHPV at follow up; positive for hrHPV at baseline and positive for low risk HPV at follow-up.